<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CYCLIZINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CYCLIZINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Nausea</span>,
                <span class="indication">Vomiting</span>,
                <span class="indication">Vertigo</span>,
                <span class="indication">Motion sickness</span>,
                <span class="indication">Labyrinthine disorders</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg up to 3 times a day, for motion sickness, take 1&#8211;2 hours before departure.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg 3 times a day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Nausea and vomiting of known cause</span>,
                <span class="indication">Nausea and vomiting associated with vestibular disorders and palliative care</span>,
            </h4>
            <p class="specificity"><span class="route">By continuous intravenous infusion or by subcutaneous infusion</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 1 month&#8211;5 years</strong><br/>
                0.5&#8211;1 mg/kg up to 3 times a day (max. per dose 25 mg), intravenous injection to be given over 3&#8211;5 minutes, for motion sickness, take 1&#8211;2 hours before departure.</li>
              <li class="dose child"><strong>For children 6&#8211;11 years</strong><br/>
                25 mg up to 3 times a day, intravenous injection to be given over 3&#8211;5 minutes, for motion sickness, take 1&#8211;2 hours before departure.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                50 mg up to 3 times a day, intravenous injection to be given over 3&#8211;5 minutes, for motion sickness, take 1&#8211;2 hours before departure.</li>
              <li class="dose child"><strong>For children 2&#8211;5 years</strong><br/>
                12.5 mg up to 3 times a day.</li>
              <li class="dose child"><strong>For children 6&#8211;11 years</strong><br/>
                25 mg up to 3 times a day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                50 mg up to 3 times a day.</li>
              <li class="dose child"><strong>For children 1 month&#8211;1 year</strong><br/>
                3 mg/kg, dose to be given over 24 hours.</li>
              <li class="dose child"><strong>For children 2&#8211;4 years</strong><br/>
                50 mg, dose to be given over 24 hours.</li>
              <li class="dose child"><strong>For children 6&#8211;11 years</strong><br/>
                75 mg, dose to be given over 24 hours.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                150 mg, dose to be given over 24 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Nausea and vomiting associated with palliative care</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150 mg, dose to be given over 24 hours.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg up to 3 times a day.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid; however, there is no evidence of teratogenicity.</p><p>The use of sedating antihistamines in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in severe liver disease&#8212;increased risk of coma.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Avoid in <xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref> (some antihistamines are thought to be safe)</li>
            <li><strong>neonates:</strong> neonate (due to significant antimuscarinic activity) in neonates</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Drowsiness,
              </p>
              <p>
                <strong>rare:</strong> Anaphylaxis, angioedema, angle-closure glaucoma, arrhythmias, blood disorders, bronchospasm, confusion, convulsions, depression, dizziness, extrapyramidal effects, hypersensitivity reactions, hypotension, liver dysfunction, palpitation, paradoxical stimulation (especially with high doses in children) in children, paradoxical stimulation (especially with high doses in the elderly) in adults, photosensitivity reactions, rashes, sleep disturbances, tremor,
              </p>
              <p>
                <strong>notKnown:</strong> Antimuscarinic effects, blurred vision, dry mouth, gastro-intestinal disturbances, hallucinations, headache, hypertension, movement disorders, oculogyric crisis, paraesthesia, psychomotor impairment, tachycardia, transient speech disorders, twitching, urinary retention,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>rare:</strong> transient paralysis,
              </p>
              <p>
                <strong>notKnown:</strong> local irritation,
              </p>
        
            <section class="advice">
              <h3 class="specificity">In adults</h3>
              <p>Elderly patients are more susceptible to side-effects.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">In children</h3>
              <p>Children are more susceptible to side-effects.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">In adults</h3>
              <p>Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">In children</h3>
              <p>Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely in children, especially with high doses. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">In children</h3>
              <p>For administration <i>by mouth</i>, tablets may be crushed.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">subcutaneous</ph> use</h3>
                <p class="title">Mixing and compatibility for the use of syringe drivers in palliative care</p>
              <p>Cyclizine may precipitate at concentrations above 10&#8239;mg/mL or in the presence of sodium chloride 0.9% <i>or</i> as the concentration of diamorphine relative to cyclizine increases; mixtures of diamorphine and cyclizine are also likely to precipitate after 24 hours.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Epilepsy
          </li>
          <li>
              <strong>:</strong>
            glaucoma in children
          </li>
          <li>
            may counteract haemodynamic benefits of opioids
          </li>
          <li>
            neuromuscular disorders&#8212;increased risk of transient paralysis with intravenous use
          </li>
          <li>
              <strong>:</strong>
            prostatic hypertrophy in adults
          </li>
          <li>
            pyloroduodenal obstruction
          </li>
          <li>
            severe heart failure&#8212;may cause fall in cardiac output and associated increase in heart rate, mean arterial pressure and pulmonary wedge pressure
          </li>
          <li>
              <strong>:</strong>
            susceptibility to angle-closure glaucoma in adults
          </li>
          <li>
            urinary retention
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Tablets not licensed for use in children under 6 years.</p><p>Injection not licensed for use in children.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CYCLIZINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            suppository,
            oral suspension,
            oral solution,

            <div id="PHP77657"><a href="../medicinalForm/PHP77657.html" data-target="#PHP77657" data-action="load">Tablet</a></div>
            <div id="PHP77652"><a href="../medicinalForm/PHP77652.html" data-target="#PHP77652" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
